EY Entrepreneur of the year-2013 FROST & SULLIVAN Best Practices-2013 Business today/YES bank Excellence Awards-2013

Eris Lifesciences Limited

Date: 06th August 2026

To **BSE Limited** Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	**To** **National Stock Exchange of India Limited** Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	**Symbol: ERIS**

SUBJECT: INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)

Dear Sir/Madam,

We would like to inform that the Company has drawn down a working capital term loan amounting to ₹64,40,00,000/- (Rupees Sixty Four Crores Forty Lakhs Only) from Axis Bank Limited to meet other short-term liabilities. The aggregate debt level of the company would, therefore, remain unchanged.

In accordance with requirement of regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para B of Part A of Schedule III and SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, details attached herein shall be taken on record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar Digitally signed by Milind Talegaonkar Date: 2026.08.06 09:20:11 +05'30'

Milind Talegaonkar
Company Secretary & Compliance Officer
Membership No: A26493
Encl: *As above*


EY Entrepreneur of the year-2013


FROST & SULLIVAN Best Practices-2013


Business today/YES bank Excellence Awards-2013

Eris Lifesciences Limited

Agreements (viz. loan agreement(s) or any other agreement(s) which are binding and not in normal course of business, revision(s) or amendment(s) and termination(s) thereof:

Sr. No.	Particulars	Details
1.	name(s) of parties with whom the agreement is entered	Axis Bank Limited ("**Bank/Axis**") and Eris Lifesciences Limited ("**Company**")
2.	purpose of entering into the agreement	The Company has today drawn down a working capital loan amounting to ₹64,40,00,000/- (Rupees Sixty Four Crores Forty Lakhs Only) from Axis Bank Limited to meet other short-term liabilities. The aggregate debt level of the company would, therefore, remain unchanged.
3.	Size of agreement	₹ 64,40,00,000/- (Rupees Sixty Four Crores Forty Lakhs Only)
4.	shareholding, if any, in the entity with whom the agreement is executed	NIL
5.	significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	NA
6.	whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	NA
7.	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	NA
8.	in case of issuance of shares to the parties, details of issue price, class of shares issued	NA
9.	in case of loan agreements:	
	➢ details of lender/borrower,	Axis Bank Limited
	➢ nature of the loan,	Working Capital Term Loan
	➢ total amount of loan granted/taken,	₹ 64,40,00,000/- (Rupees Sixty Four Crores forty Lakhs Only)
	➢ total amount outstanding,	Term Loan: 91.37 Crores Working Capital Loan: 55 Crores
	➢ date of execution of the loan agreement/sanction letter	The Sanction letter is executed on 05th August 2026.
	➢ details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed	The Bank willl have a second charge on assets (both primary and collateral) already created for its existing working capital credit facilities.

Registered & Corporate Office:
Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

	from a party become material on a cumulative basis;	
10.	any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	NA
11.	in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): i. name of parties to the agreement; ii. nature of the agreement; iii. date of execution of the agreement; iv. details of amendment and impact thereof or reasons of termination and impact thereof.	NA